Biology Atlas

Map / Modalities

modality · intermediate · partly written

CAR T cell therapy

CAR T cell therapy is a patient's own T cells, given a receptor gene outside the body and returned by infusion, to attack cells that carry one chosen surface protein.

Also called: CAR T, chimeric antigen receptor T cell therapy

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

CAR T in one breath

A patient's own T cells get a gene for a receptor aimed at one surface protein, are multiplied outside the body and returned by drip. They kill cells carrying that protein, and they keep dividing, so it is a living drug. In a trial of 75 young patients with relapsed leukemia, 81% went into remission within three months. 12

Reported, not yet replicated

His first guess: what CAR T is

He said: "CAR T therapy, which I'm not sure what that does. I think that's for cancers, but it eats those cells by engineering the T cells to go after the right cells." 3

Amit's hypothesis

Checked against the sources more

Correct in outline: the products below are used in blood cancers, and the T cells are engineered to recognise one surface protein. Two corrections. First, the cell does not only eat: on meeting CD19 it releases cytokines and divides, so it expands and can persist for months to years (20 months in ELIANA). Second, the target is not unique to the cancer: normal B cells carry CD19 and are killed too, with low antibodies (hypogammaglobulinemia) as a result. It is also not only for cancers by definition: the approved products in these sources are cancer drugs, but this record covers only those. 142

Reported, not yet replicated

What the engineering physically is more

One synthetic protein, the CAR. Outside: a single-chain antibody fragment (in these products mouse-derived) that binds CD19. Through the membrane and inside: CD3 zeta, the go signal, plus a costimulatory domain. A normal T cell needs the target peptide displayed on HLA; the CAR bypasses that, which matters because tumours often hide HLA. A lentiviral vector (tisagenlecleucel) or a gamma-retroviral vector (axi-cel) inserts the CAR gene into the cell's DNA, so daughter cells inherit it.

Where the gene lands can matter. In one patient with chronic lymphocytic leukemia, 94% of the CAR T cells at the response peak came from a single clone in which vector insertion had disrupted TET2; that patient also carried a hypomorphic mutation in the other TET2 allele. It is one patient, but it makes insertion site a hidden variable, as in other integrating gene therapies (see modalities/gene-therapy). 256

Reported, not yet replicated

How the cells are given more

Blood is taken by leukapheresis, cells are engineered and expanded, and the product is returned, usually frozen. Days before infusion the patient receives lymphodepleting chemotherapy. The infusion is intravenous and the cells home to marrow, nodes and tumour on their own: nothing is placed. Peak CAR T expansion overlaps with the toxicities. Cytokine release syndrome occurred in 77% of ELIANA patients (48% of them received tocilizumab) and neurologic events in 40%; in ZUMA-1 grade 3 or higher CRS was 13% and neurologic events 28%. 175

Reported, not yet replicated

Why chemotherapy comes first more

The standard reason is to make room and cytokines (IL-7, IL-15) for the infused cells and to remove host lymphocytes. The evidence in the sources: in 32 adults with lymphoma, adding fludarabine to cyclophosphamide improved CAR T expansion and persistence, and it suppressed an immune response to the mouse-derived binder that had limited expansion. A later study linked higher-intensity lymphodepletion and a favourable cytokine profile (MCP-1 and IL-7 above median) to better progression-free survival. The chemotherapy is therefore about expansion, not about stopping rejection of the patient's own cells. See concepts/lymphodepletion. 89

Reported, not yet replicated

His second question

He asked: "For CAR T cells, how do you inject them into the body so that your body doesn't reject those CAR T cells that it considers foreign?" 3

Amit's hypothesis

Why a patient's own cells are not rejected more

The two approved examples here are autologous: the cells carry the patient's own HLA, so the immune system sees self and there is no donor-versus-host mismatch. The residual foreign part is the mouse-derived binder in the CAR. The FDA review of tisagenlecleucel reports antibodies against it before infusion in 86% of patients and induced or boosted antibodies in 37%, with no apparent effect on expansion, response or relapse in that study. In the lymphoma study, fludarabine blunted an immune response to the binder. This answers the question for autologous products; see concepts/graft-rejection-and-immunosuppression for the general case. 28

Reported, not yet replicated

Donor cells (allogeneic): what is and is not known here deep

Donor-derived CAR T cells face two attacks: donor T cells can attack the host, and the host can reject the donor cells. This is the general logic of grafts, written up in concepts/graft-rejection-and-immunosuppression. The specific fixes in development (editing out the donor T-cell receptor, adding a depleting antibody to the regimen) and their trial results were not confirmed against a primary source that could be opened for this record, so they are left out rather than stated. 2

Our inference

Where it breaks deep

A single target is a single point of failure: a tumour that stops making CD19 escapes (no rate was found in the sources opened). Patients wait weeks for manufacture and a fraction are never treated. The efficacy figures come from single-arm trials with different denominators, so read which one a rate uses; in ELIANA the FDA's efficacy set differed from the paper's 75 patients. Fatal cerebral edema is not confined to one failed product (see drugs/jcar015). On 28 Nov 2023 FDA reported T-cell malignancies after BCMA- or CD19-directed autologous CAR T products, class-wide, and kept the view that benefit outweighs risk for approved uses. 257110

Reported, not yet replicated

What it is

A living cell product. The patient's own T cells are collected, a gene for a chimeric antigen receptor (CAR) is added outside the body, and the cells are multiplied and given back. The receptor has an outer antibody-derived binder aimed at a surface protein (CD19 in the products below), and inside it a CD3 zeta activation signal plus a costimulatory domain (4-1BB in tisagenlecleucel, CD28 in axicabtagene ciloleucel). 25

Reported, not yet replicated

Intervenes at

Same as small molecule

The logic of choosing a target is the same: a protein on the disease cell is picked, and the question is whether hitting it helps more than it harms. Efficacy and safety are still read from trials with response rates and adverse events. What it shares least is the idea of a fixed dose. 17

Our inference

Changes downstream

Manufacture is per patient: collection, gene delivery by a lentiviral or gamma-retroviral vector, expansion, release testing and shipping. Manufacturing is a result of its own: for axi-cel, product was made for 110 of 111 enrolled patients and given to 101; the FDA review of tisagenlecleucel reports about 9% of lots failing. The median time from collection to delivered product in ZUMA-1 was 17 days (range 14 to 51). Because the cells divide after infusion, the dose given on day 0 and the exposure later differ: higher CAR T levels in blood went with response in ZUMA-1. No potency assay is described in the sources opened; this is an open question. 725

Reported, not yet replicated

Delivery

Collection by leukapheresis; then, before infusion, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine in ZUMA-1; see concepts/lymphodepletion); then an ordinary intravenous infusion of one bag, with no surgery. The cells find marrow, nodes and tumour by themselves. In the lymphoma study of 32 adults, cyclophosphamide plus fludarabine gave more CAR T expansion and persistence and 50% complete remission versus 8% with cyclophosphamide alone. 582

Reported, not yet replicated

Persistence

The cells divide and carry the gene to daughter cells, so one infusion can keep acting. In ELIANA, CAR T cells were seen in blood for as long as 20 months; in two patients with chronic lymphocytic leukemia, more than ten years. There is no simple off switch: the sources opened describe only treating the toxicities (tocilizumab, supportive care), and the FDA requires 15 years of follow-up. 14210

Reported, not yet replicated

Examples

Teach this

In one sentence

CAR T therapy engineers a patient's own T cells to recognise one surface protein and returns them by infusion, where they kill and multiply. 12

Reported, not yet replicated

The five-minute version

Collect the patient's T cells, add a CAR gene with a viral vector, grow them and infuse them after lymphodepleting chemotherapy. The cells home by themselves, meet CD19, kill, divide and can persist for months or years. They are not rejected because they are the patient's own; the chemotherapy makes room for them to expand. The same activation causes cytokine release syndrome and neurologic toxicity, and one product, JCAR015, was stopped after deaths from brain swelling. 182

Reported, not yet replicated

The common wrong idea

CAR T cells are foreign cells that the body has to be stopped from rejecting, and they just eat cancer.

The cells are the patient's own and are not rejected; the chemotherapy beforehand is for expansion, and the cells then multiply and persist as a living drug rather than acting like a fixed dose.

The one citation to hand over: 1

Still open here

Linked from

Sources

  1. Maude, S. L., et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine (2018). paper; opened 2026-11-17 all records citing this
  2. FDA Summary Basis for Regulatory Action: Kymriah (tisagenlecleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
  4. Melenhorst, J. J., et al.. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature (2022). paper; opened 2026-11-17 all records citing this
  5. FDA Summary Basis for Regulatory Action: Yescarta (axicabtagene ciloleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  6. Fraietta, J. A., et al.. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature (2018). paper; opened 2026-11-17 all records citing this
  7. Neelapu, S. S., et al.. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine (2017). paper; opened 2026-11-17 all records citing this
  8. Turtle, C. J., et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine (2016). paper; opened 2026-11-17 all records citing this
  9. Hirayama, A. V., et al.. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood (2019). paper; opened 2026-11-17 all records citing this
  10. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous CAR T Cell Immunotherapies. FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (2)

This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/modalities/car-t.json